As is widely known, the Administration in the United States has placed a ban on the use of fetal tis sue for clinical transplantation research. This ban does not limit the use of federal funds or federally funded research facilities for basic science research using fe tal tissue, nor does it ban the use of fetal tissue for clinical research that is funded through other mecha nisms (14) .
Removal of National Institute of Health (NIH)
funding from such clinical research guarantees that the peer review process for fetal tissue research will be dis seminated to multiple other forms, all of which will be outside of the auspices of the federal government (17) . As argued by Annas and Elias (1) , "This means that fetal tissue will be used in transplant research, as em bryos have been used before it, in an uncoordinated manner, without peer review or oversight by the NIH, generally outside the arena of public debate, and in a manner that is suboptimal from both a scientific and an ethical perspective." This is quite similar to what happened with in vitro fertilization research (7) . As previously argued in the popular press, the ban has the potential to delay significant medical research on im portant diseases for several years and possibly influ ence patients to leave the United States to receive modern medical therapy.
It has been argued that the ban itself may be in di rect violation of the NIH's own rules (3, 15) . This ban is also being challenged at the legislative level. In 1992 the U.S. House of Representatives and the U.S. Sen ate passed legislation that would allow for the fund ing of clinical fetal tissue research. The legislation in the Senate passed with enough votes to override a pres idential veto, whereas the House vote fell just short of that necessary to override a veto (14 votes). Within 1 wk before the House vote, the Administration re leased its plan for the development of fetal tissue banks. These banks are to be created solely for the purpose of using tissue derived from spontaneous abortions and ectopic pregnancies, as opposed to vol untary abortions.
Almost all fetal tissue transplant programs through out the world have resorted to using tissue derived from voluntary abortions. There are significant obsta cles to the use of spontaneous abortions for transplan tation purposes (9), which include:
Up to 50% of cases of spontaneous abortions are known to have chromosomal abnormalities (20). 2. Spontaneous abortions are often secondary to in utero infections, therefore increasing the risk of transplant-related infections (18). 3. Passage of the fetus through the vaginal canal dur
ing a spontaneous abortion further increases the likelihood for bacterial contamination of the donor material. Sterility of tissue can be more easily con trolled during voluntary abortions (6,12). 4. The majority of spontaneous abortions often are preceded by fetal death in utero (11, 19) . This in creases the likelihood of transplanting a nonviable graft.
In some situations, optimal transplant survival is
closely related to specific donor ages (4,8). In the case of embryonic neural transplantation for the symptomatic treatment of Parkinson's disease, this window is most likely limited to 6.5-to 9-postovulatory wks (5,10). This age range represents only a small percentage of spontaneous abortions.
6. Staging of embryonic age is difficult, as spontane ously aborted fetuses are frequently abnormally small (13). This parameter is used in dating embry onic age (10).
7. The timing of surgical procedures would be quite complex logistically, given the unpredictability of spontaneous abortions. This factor also creates lo gistic and safety problems for adequate serologic testing for human immunodeficiency virus, hepa titis, cytomegalo virus, and herpes in the putative mother and the fetus (10).
8.
For some diseases, it may be necessary to trans plant more than one fetus per patient (12) . The use of spontaneously aborted tissue may hamper the ability to provide multiple donors simultaneously.
Although the obstacles to the use of spontaneous tissue are formidable, they are not necessarily insur mountable. It has been noted that out of 3,500 spon taneously aborted tissue samples examined over a 4j-yr period, between 8 and 251 samples would be useful for transplantation purposes (16). This estimate does not take into account the limited useful age range of donors, or potential bacterial or viral contamina tion, which as mentioned above, are significantly com mon problems in tissue that is spontaneously aborted and passes through the vaginal canal. It is therefore likely that only 1 to 25 useful specimens could be pro vided annually.
Given the small number of samples that would be available per year, clearly large-scale cell proliferation seems necessary if the use of spontaneously aborted tissue is to be a viable alternative. This type of work is highly investigative and will require years of research with far larger quantities of fetal tissue than are avail able strictly from spontaneous abortions and ectopic pregnancies.
The NIH request for grants (RFA #HD-92-10) for the human fetal tissue bank delineates several impor tant goals for the establishment of a bank utilizing products from spontaneous abortions and ectopic pregnancies. It sets objectives for developing tissue banks, establishing methods of testing tissue for qual ity control purposes (genetic, infectious, and viability testing), culturing and proliferation of tissue, preserv ing tissue long term, and transporting tissue before transplantation. These scientific goals are in addition to the objectives of studying the epidemiology and un derlying mechanisms of early pregnancy loss.
Unfortunately, the request for application (RFA) requires that all research be performed with products of spontaneous abortions or ectopic pregnancies, and specifically excludes the use of electively aborted tis sue for any of the basic science research required for establishment of the tissue bank. The minimal require ments for the success of the program include signif icant tissue proliferation and tissue storage. These techniques can only be studied with significant quan tities of tissue that may not be available using the RFA guidelines, per se. It is of interest that in all other grants, the NIH allows funding for this type of basic research in animals using fetal tissue from elective abortions (14) .
Clearly this project is a high priority for the NIH. The RFA was dated June 12, 1992 requiring an appli cation receipt dated August 3, 1992, with the distribu tion of funds on September 28, 1992. A total of 3 million dollars is to be awarded, divided among up to six principal investigators and covering a 2-yr period.
It should not be forgotten in this debate that it re mains legal to perform clinical transplant programs using fetal tissue. The only issue being debated is whether or not this will be funded by NIH. It is impor tant to learn from the similar problems encountered by researchers in the field of in vitro fertilization, who initially lacked a forum for establishing a peer review process, as well as uniform guidelines for use of fetal tissue. It has been argued that "local institutional review boards provide inadequate protection to the subject of [transplantation] research, just as they failed to protect the subject of recent experiments with artificial hearts and xenografts [and autologous adrenal grafts]" (2).
In the absence of an established NIH peer review process, we therefore propose that scientific leaders from each field of fetal tissue research form a Practice Committee specifically to address the many issues re 
